New approaches in the management of spasticity in multiple sclerosis patients: Role of cannabinoids

Therapeutics and Clinical Risk Management

Volumn 6, Issue 1, 2010, Pages 59-63

  Smith, Paul F ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Cannabinoids; Cannabis; Multiple sclerosis; Spasticity

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; BETA INTERFERON; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABIS; DRONABINOL; NABILONE; PLACEBO;

ALLERGIC ENCEPHALOMYELITIS; ANTICONVULSANT ACTIVITY; ATTENTION; BLURRED VISION; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DIZZINESS; DRUG ACTIVITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; HUMAN; INTOXICATION; MOTOR NEURON DISEASE; MULTIPLE SCLEROSIS; MUSCLE TONE; NAUSEA; NERVE EXCITABILITY; NONHUMAN; PRESYNAPTIC NERVE; PSYCHOSIS; REACTION TIME; REVIEW; SIDE EFFECT; SOMNOLENCE; SPASTICITY; TREMOR; VERTIGO; WORKING MEMORY; XEROSTOMIA;

EID: 77950850216     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/tcrm.s5974     Document Type: Review

References (44)

1. Pertwee RG. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol. 2009;156(3):397-411.
2. Kreitzer AC, Regehr WG. Retrograde signalling by endocannabinoids. Curr Opin Neurobiol. 2002;12:324-330.
3. Alger BE. Retrograde signalling in the regulation of synaptic transmission: focus on endocannabinoids. Prog Neurobiol. 2002;68: 247-286.
4. Baker D, Pryce G, Croxford JL, et al. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J. 2001;15:300-302.
5. Baker D, Pryce G, Croxford JL, et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature. 2000;404:84-87.
6. Berrendero F, Sanchez A, Cabranes A, et al. Changes in cannabinoid (CB1) receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis. Synapse. 2001;41:195-202.
7. Baker D, Pryce G. The endocannabinoid system and multiple sclerosis. Curr Pharm Des. 2008;14(23):2326-2336.
8. British Medical Association. Therapeutic Uses Of Cannabis. Amsterdam: Harwood Academic Publishers; 1997.
9. Consroe P, Musty R, Rein J, et al. The perceived effects of smoked Cannabis on patients with multiple sclerosis. Eur Neurol. 1997;38: 44-48.
10. Hall WD, Degenhardt LJ, Currow D. Allowing the medical use of Cannabis. Med J Aust. 2001;175:39-40.
11. Smith PF. Cannabinoids for the treatment of multiple sclerosis: No smoke without fire? Exp Rev Neurotherapeutics. 2003;3:327-357.
12. Smith PF. Medicinal Cannabis extracts for the treatment of multiple sclerosis. Curr Opin Investig Drugs. 2004;5:727-730.
13. Killestein J, Hoogervorst ELJ, Reif M, et al. Safety, tolerability and efficacy of orally administered cannabinoids in MS. Neurol. 2002;58:1404-1407.
14. Zajicek J, Fox P, Sanders H, et al. Cannabinoids for the treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre, randomised placebo-controlled trial. Lancet. 2003;362:1517-1526.
15. Zajicek JP, Sanders HP, Wright DE, et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow-up. J Neurol Neurosurg Psychiat. 2005;76:1664-1669.
16. Wade DT, Robson P, House H, et al. A preliminary controlled study to determine whether whole-plant Cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil. 2003;17:21-29.
17. Wade DT, Makela P, Robson P, et al. Do Cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Multiple Sclerosis. 2004;10:434-441.
18. Killestein J, Polman C. The therapeutic value of cannabinoids in MS: real or imaginary? Multiple Sclerosis. 2004;10:339-340.
19. Vaney C, Heinzel-Gutenbrunner M, Jobin P, et al. Efficacy, safety and tolerability of an orally administered Cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Multiple Sclerosis. 2004;10:417-424.
20. Brady CM, DasGupta R, Dalton C, et al. An open-label pilot study of Cannabis based extracts for bladder dysfunction in advanced multiple sclerosis. Multiple Sclerosis. 2004;10:425-433.
21. Collin C, Davies P, Mutiboko IK, et al; Sativex Spasticity in MS Study Group. Randomised controlled trial of Cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol. 2007;14: 290-296.
22. Wissel J, Haydn T, Muller J, et al. Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain. J Neurol. 2006;253(10):1337-1341.
23. Hagenbach U, Luz S, Ghafoor N, et al. The treatment of spasticity with Delta-9-tetrahydrocannabinol in persons with spinal cord injury. Spinal Cord. 2007;45(8):551-562.
24. Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Systematic Reviews. 2000;4: CD001332.
25. Smith PF. Evaluation of Sativex (GW-1000). IDdb3 Current Drugs Database. http://www.iddb3.com 2004:1-19.
26. Smith PF. Sativex (GW-1000). Current Opinion in Investigational Drugs. 2004;5:748-754.
27. Wade DT, Makela PM, House H, et al. Long-term use of a Cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Multiple Sclerosis. 2006;12(5):639-645.
28. Aragona M, Onesti E, Tomassini V, et al. Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a doubleblind, placebo-controlled, crossover study. Clin Neuropharmacol. 2009;32(1):41-47.
29. Campbell FA, Tramer MR, Caroll D, et al. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. Brit Med J. 2001;323:13-16.
30. Tramer MR, Caroll D, Campbell FA, et al. Cannabinoids for control of chemotherapy-induced nausea and vomiting: quantitative systematic review. Brit Med J. 2001;323:16-21.
31. Fergusson D, Poulton R, Smith PF, et al. Cannabis and psychosis. Brit Med J. 2006;332:172-175.
32. Moore THM, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet. 2007;370:319-328.
33. Fried PA, Watksinson B. Differential effects on facets of attention in adolescents prenatally exposed to cigarettes and marihuana. Neurotoxicol Teratol. 2001;23:421-430.
34. Fried PA, Smith AM. A literature review of the consequences of prenatal marihuana exposure. An emerging theme of a deficiency in aspects of executive function. Neurotoxicol Teratol. 2001;23:1-11.
35. Fried PA, Watkinson B, Gray R. Differential effects on cognitive functioning in 13-to 16 year-olds prenatally exposed to cigarettes and marihuana. Neurotoxicol Teratol. 2003;25:427-436.
36. Goldschmidt L, Richardson GA, Cornelius MD, et al. Prenatal marijuana and alcohol exposure and academic achievement at age 10. Neurotoxicol Teratol. 2004;26:521-532.
37. Goldschmidt L, Day NL, Richardson GA. Effects of prenatal marijuana exposure on child behavior problems at age 10. Neurotoxicol Teratol. 2000;22:325-336.
38. Smith AM, Fried PA, Hogan MJ, et al. Effects of prenatal marijuana on response inhibition: an fMRI study of young adults. Neurotoxicol Teratol. 2004;26:533-542.
39. Newsham-West D, Darlington CL, Smith PF. Potent effects of a selective cannabinoid receptor agonist on some medial vestibular nucleus neurons. Eur J Pharmacol. 1998;348:R1-R2.
40. Ashton JC, Zheng Y, Liu P, et al. Immunohistochemical characterization and localization of cannabinoid CB1 receptor protein in the rat vestibular nucleus complex and effects of unilateral vestibular deafferentation. Brain Res. 2004;1021:266-273.
41. Pryce G, Baker D. Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors. Br J Pharmacol. 2007;150(4):519-525.
42. Whalley BJ, Wilkinson JD, Williamson EM, et al. A novel component of Cannabis extract potentiates excitatory synaptic transmission in rat olfactory cortex in vitro. Neurosci Letts. 2004;365:58-63.
43. Wilkinson JD, Whalley BJ, Baker D, et al. Medicinal Cannabis: Is delta-9-tetrahydrocannabinol necessary for all its effects? J Pharm Pharmacol. 2003;55:1687-1694.
44. Lienau FS, Füllgraf H, Moser A, et al. Why do cannabinoids not show consistent effects as analgetic drugs in multiple sclerosis? Eur J Neurol. 2007;14:1162-1169.